Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 clinical trials
Also written JS207.
Its developmentBy Wigen Biomedicine Technology (Shanghai) and Mabwell (Shanghai) Bioscience, step by step2 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- JS207
- 8
Studies by the year they started
12 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 6 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 10
Shanghai Junshi Bioscience Co., Ltd. (9) · Wigen Biomedicine Technology (Shanghai) Co., Ltd. (1) · Fudan University (1) · Mabwell (Shanghai) Bioscience Co., Ltd. (1)
Often tested with
Tested in the same studies.
WJ47156 (1) · Toripalimab (1) · Bevacizumab (1) · JS007 (1) · JS212 (1) · WJB001 (1) · Dalpiciclib (1) · Pyrotinib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test Anti-PD-1/Anti-VEGF Bispecific Antibody JS207.
- Nov 2026A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal CancerPhase 2 · Shanghai Junshi Bioscience Co., Ltd.
- Dec 2026Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid TumorsPhase 1 · Shanghai Junshi Bioscience Co., Ltd.
- Apr 2027JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLCPhase 2 · Shanghai Junshi Bioscience Co., Ltd.
Studies
Open first, then newest update. How each study uses Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)RecruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT07876557Written as JS212 in combination with JS207How we know
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid TumorsRecruitingPhase 1/2Wigen Biomedicine Technology (Shanghai) Co., Ltd.NCT06953323Written as WJB001 Capsules+Paclitaxel+carboplatin+JS207/ToripalimabHow we know
- JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver CancerNot yet recruitingPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT07823348Written as JS207How we know
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as JS207How we know
- JS207 Combination Therapy in Triple-negative Breast CancerRecruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT07045311Written as JS207 in combination with 9MW2821How we know
- A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid TumorsRecruitingPhase 1/2Mabwell (Shanghai) Bioscience Co., Ltd.NCT07466160Written as JS207How we know
- JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT06954467Written as JS207How we know
- A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal CancerRecruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT06885385Written as JS207How we know
- Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and ImmunotherapyTerminatedPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT06924606Written as JS207 injection +docetaxelHow we know
- JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLCActive, not recruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT06944470Written as JS207How we know
- Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid TumorsActive, not recruitingPhase 1Shanghai Junshi Bioscience Co., Ltd.NCT06571422Written as JS207How we know
- The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant TumorActive, not recruitingPhase 1Shanghai Junshi Bioscience Co., Ltd.NCT06022250Written as JS207How we know
Given beside what is tested · 6 — Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 is usual care or a partner of the new treatment
- JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal CarcinomaRecruitingPhase 2Chinese University of Hong KongNCT07690787Written as JS207How we know
- Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid TumorsRecruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT07480733Written as JS207 for InjectionHow we know
- Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI TherapyRecruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT06868836Written as JS207How we know
- A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung CancerRecruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT07309276Written as JS207 for InjectionHow we know
- JS212 Combination Therapies in Metastatic Colorectal CancerRecruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT07503756Written as JS207How we know
- JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLCActive, not recruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT06969027Written as JS207How we know
What changed recently
From the registry's own updates since Oct 20, 2026.